issues
September 2011
Download PDFTABLE OF CONTENTS
Beyond the Headlines: AstraZeneca, Pfizer,
Derek G. Hennecke, MBA, continues with part 5 of his latest 6-part series on how not to blow the recovery!
DDEP Sales & Prescription Performance 2010, Hints of the Future
Josef Bossart, PhD, examines some key trends that defined 2010 and tries to understand how these figures may impact business going forward.
New Data Shows Drug Delivery Has Positive Impact on Patient Compliance
Steven Hamlen, MBA, and Karen MacGregor, PhD, outline the impact of drug delivery formulation selection on cost to patients and our healthcare system, therapeutic product profile performance, and patient adherence to their prescription medication in a data-driven case study.
Fethi Trabelsi, PhD, highlights the importance of pharmacokinetics/pharmacodynamics studies in the “similarity assessment” during biosimilar clinical development.
MacuClear, Inc: Discovering & Developeing a Novel Solution for Dry Age-Related Macular Degeneration
Drug Development Executive: Philip Ralston, CEO of MacuCLEAR, discusses his company’s unique, yet practical approach to treating Dry AMD.
The Zeta Potential & its Use in Pharmaceutical Applications – Part 2: Measurement Techniques & Uses
David Fairhurst, PhD, and Robert W. Lee, PhD, covered in part 1 charged interfaces (in both polar and non-polar media) and introduced the concept of the zeta potential (ZP). In this concluding part 2, they discuss techniques to measure ZP and illustrate the utility of its measurement.
Biologics, Self-Administration & Patient Adherence: Creating a Lucrative Hand-Held Injection Market
Special Feature: Contributor Cindy H. Dubin heads up a roundtable discussion with some of the industry’s leading hand-held injection companies to find out about what’s driving the market, their respective development projects, and where they see the sector headed in the next few years.
Contract Research Outsourcing Market: One of the Fastest Growing Segments in the Pharmaceutical/Biotechnology Industry
Frost & Sullivan Analysts Jennifer Brice and Barath Shankar Subramanian talk about competition in the growing CRO market and the continued search for new growth and expansion opportunities as pricing pressure continues to remain a major factor affecting profitability.
Clusters’ Last Stand?
Andrew MacGarvey says clusters of businesses in the biotech community have existed for many years, and while this has been a boon for the human resources teams at these pharmaceutical and biotech companies, it is not necessarily in the best interest of the company as a whole, due to the innovation challenge it presents.
Biovista, Inc: Drug Indication Expansion & Adverse Event Profiling as a Viable Business Model
Executive Summary: Dr. Aris Persidis, President & Co-Founder of Biovista, discusses how indication expansion (also known as drug repositioning) practiced in a rational and systematic manner generates a new kind of IP, innovation, market opportunity, market barrier, and competitor differentiation.
DEPARTMENTS
Market News & Trends
Excipient Update
The New Era of Functional Excipients: An Innovative Approach in Dosage Form Design
Technology & Services Showcase
External Delivery
Teachers
COVER
FEATURES
